Active Filter(s):
Details:
This U.S. Phase 2/3 study will examine the safety and efficacy of RedHill Biopharma's RHB-107 (upamostat), using ObvioHealth's clinical trial ecosystem, including digital devices, a patient-centric smartphone application and home healthcare visits.
Lead Product(s): Upamostat
Therapeutic Area: Infections and Infectious Diseases Product Name: RHB-107
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: RedHill Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021